文献速递乳腺癌

HER2阳性导管原位癌保乳术后放疗联合曲妥珠单抗的III期随机对照试验

Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
PubMed 文献 · J Clin Oncol · 2021-03-19

B-43试验纳入2014例保乳术后HER2阳性导管原位癌患者,随机接受单纯全乳放疗或放疗同步曲妥珠单抗。

要点

  • 放疗联合曲妥珠单抗未显著降低同侧乳腺癌事件风险,HR 0.81。
  • 浸润性复发与DCIS复发的HR分别为1.11和0.68,均无统计学意义。
  • 该方案暂不推荐作为HER2阳性DCIS保乳术后的常规治疗。

核心结论

  • 放疗联合曲妥珠单抗未达到降低36%同侧乳腺癌事件的主要目标,仅显示19%的非显著性降低,试验为阴性。

研究设计与样本

  • III期随机对照试验,纳入2014例保乳术后HER2阳性导管原位癌患者,随机接受单纯全乳放疗或放疗同步曲妥珠单抗。
  • 分层因素包括绝经状态、辅助内分泌治疗计划和核分级,主要分析计划在发生163例同侧乳腺癌事件或全部患者随访≥5年时进行。

主要发现

  • 年同侧乳腺癌事件率:单纯放疗组0.99%/年,联合组0.79%/年。

临床怎么用

  • 对于保乳术后HER2阳性DCIS患者,放疗同步曲妥珠单抗不应作为常规治疗推荐。

局限性

  • 研究未达到方案预设的163例事件数,最终分析由所有患者随访≥5年触发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preclinical studies report that trastuzumab (T) can boost radiotherapy (RT) effectiveness. The primary aim of the B-43 trial was to assess the efficacy of RT alone vs concurrent RT plus T in preventing recurrence of ipsilateral breast cancer (IBTR) in women with ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: Eligibility: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, DCIS resected by lumpectomy, known estrogen receptor (ER) and/or progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status by centralized testing. Whole-breast RT was given concurrently with T. Stratification was by menopausal status, adjuvant endocrine therapy plan, and nuclear grade. Definitive intent-to-treat primary analysis was to be conducted when either 163 IBTR events occurred or all accrued patients were on study ≥ 5 years. RESULTS: There were 2,014 participants who were randomly assigned. Median follow-up time as of December 31, 2019, was 79.2 months. At primary definitive analysis, 114 IBTR events occurred: RT arm, 63 and RT plus T arm, 51 (hazard ratio [HR], 0.81; 95% CI, 0.56 to 1.17; P value = .26). There were 34 who were invasive: RT arm, 18 and RT plus T arm, 20 (HR, 1.11; 95% CI, 0.59 to 2.10; P value = .71). Seventy-six were DCIS: RT arm, 45 and RT plus T arm, 31 (HR, 0.68; 95% CI, 0.43 to 1.08; P value = .11). Annual IBTR event rates were: RT arm, 0.99%/y and RT plus T arm, 0.79%/y. The study did not reach the 163 protocol-specified events, so the definitive analysis was triggered by all patients having been on study for ≥ 5 years. CONCLUSION: Addition of T to RT did not achieve the objective of 36% reduction in IBTR rate but did achieve a modest but statistically nonsignificant reduction of 19%. Nonetheless, this trial had negative results. Further exploration of RT plus T is needed in HER2-positive DCIS before its routine delivery in patients with DCIS resected by lumpectomy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cobleigh MA, Anderson SJ, Siziopikou KP, et al. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021. PMID: 33739848. doi:10.1200/JCO.20.02824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。